Nature Medicine
3, 526 - 532 (1997)
doi:10.1038/nm0597-526
Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccinationJean D. Boyer1, *, Kenneth E. Ugen2, *, Bin Wang1, Michael Agadjanyan1, Lori Gilbert1, Mark L. Bagarazzi3, Michael Chattergoon1, Patrice Frost4, Ali Javadian4, Williams V. Williams5, Yosef Refaeli6, Richard B. Ciccarelli7, Daniel Mccallus7, Leslie coney7
& David B. Weiner1
1Department of Pathology and Laboratory Medicine, University of Pennsylvania, SOS Stellar-Chance Building, 422 Curie Boulevard, Philadelphia, Pennsylvania, 19104, USA
2Department of Medical Microbiology and Immunology, University of South Florida, MDC10 12901 Bruce B. Downs Boulevard, Tampa, Florida, 33612, USA
3Department of Pediatrics, University of Pennsylvania, 505 Stellar-Chance Building, 422 Curie Boulevard, Philadelphia Pennsylvania, 19104, USA
4White Sands Research Center, Coulston Foundation, 1300 Lavelle Road, Alamogordo, New Mexico, 88310, USA
5Hospital of the University of Pennsylvania, 912 Stellar-Chance Building, 422 Curie Boulevard, Philadelphia, Pennsylvania 19104, USA
6Department of Pathology, Harvard University, LMRC-5, 221 Longwood Avenue, Boston, Massachusetts 02115, USA
7Apollon Inc., 1 Great Valley Parkway, Malvern, Pennsylvania, 19355, USA
*These authors contributed equally to this manuscript. Novel approaches for the generation of more effective vaccines for HIV-1 are of significant importance. In this report we analyze the immunogenicity and efficacy of an HIV-1 DNA vaccine encoding env, rev and gag/pol in a chimpanzee model system. The immunized animals developed specific cellular and humoral immune responses. Animals were challenged with a heterologous chimpanzee titered stock of HIV-1 SF2 virus and followed for 48 weeks after challenge. Polymerase chain reaction coupled with reverse transcription (RT-PCR) results indicated infection in the control animal, whereas those animals vaccinated with the DNA constructs were protected from the establishment of infection. These studies serve as an important benchmark for the use of DNA vaccine technology for the production of protective immune responses.
REFERENCES
- Haynes, B.F., Pantaleo, C.,& Fauci, A.S. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271, 324−328 (1996). | PubMed | ISI | ChemPort |
- Pantaleo, G. et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332, 209−216 (1995). | Article | PubMed | ISI | ChemPort |
- Rinaldo, C. et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J. Virol. 69, 5838−5842 (1995). | PubMed | ISI | ChemPort |
- Rowland-Jones, S. et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med. 1, 59−64 (1995). | Article | PubMed | ISI |
- Rowland-Jones, S., Nixon, D. & Aldhous, M. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 341, 860−861 (1993). | Article | PubMed | ChemPort |
- Ugen, K.E. et al. Verticaltransmissionofimmunodeficiency virus type 1: Seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope. J. Infect. Dis. 175, 63−69 (1997). | PubMed | ISI | ChemPort |
- Ugen, K.E. et al. Vertical transmission of human immunodeficiency virus (HIV) infection: Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J. Clin. Invest. 89, 1923−1930 (1992). | PubMed | ISI | ChemPort |
- Rossi, P. et al. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gpl 20 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc. Not. Acad. Sci. USA 86, 8055−8058 (1989). | ChemPort |
- Goedert, J. et al. Mother-to-infant transmission of human immunodeficiency virus type 1: Association with prematurity or low anti-gp!20. Lancet 2, 1351−1354 (1989). | Article | PubMed | ISI | ChemPort |
- Dubensky, T., Campell, B. & Villarreal, L. Direct transfection of viral and plasmid DNA into the liver of spleen of mice. Proc. Natl. Acad. Sci. USA 81, 7529−7533 (1984). | PubMed | ChemPort |
- Raz, E. et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc. Natl. Acad. Sci. USA 90, 4523 (1993). | PubMed | ChemPort |
- Wolff, J.A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465−1468 (1990). | PubMed | ISI | ChemPort |
- Wang, B. et al. Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Hum. Gene Ther. 6, 407−418 (1995). | PubMed | ISI | ChemPort |
- Ulmer, J.B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745−1749 (1993). | PubMed | ISI | ChemPort |
- Tang, D.C., Devit, M. & Johnston, S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152−154 (1992). | Article | PubMed | ISI | ChemPort |
- Michel, M.L. et al. DNA-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl. Acad. Sci. USA 92, 5307−5311 (1995). | PubMed | ChemPort |
- Lowrie, D.B., Tascon, R.E., Colston, M.J. & Silva, C.L. Towards a DNA vaccine against tuberculosis. Vaccine 12, 1537−1540 (1994). | Article | PubMed | ISI | ChemPort |
- Barry, M., Lai, W. & Johnston, S. Protection against mycoplasma infection using expression-library immunization. Nature 377, 632−635 (1995). | Article | PubMed | ISI | ChemPort |
- Fynan, E.F., Webster, R.G., Fuller, D.H. & Haynes, J.R. DNA vaccines: Protective immunizations by parental, mucosal and gene-gun inoculations. Proc. Natl. Acad. Sci. USA 90, 11478−11482 (1993). | PubMed | ChemPort |
- Wang, B. et al. DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells. AIDS Res. Hum. Retroviruses 10 (Suppl. 2), S35−S41 (1994). | PubMed | ISI | ChemPort |
- Wang, B. et al. DNA Inoculation induces cross clade anti-HIV-1 responses. Ann. NY Acad. Sci. 772, 186−197 (1995). | PubMed | ChemPort |
- Wang, B. et al. Induction of humoral and cellular immune responses to the human immunodeficiency virus type 1 in non-human primates. Virology 221, 102−112 (1995). | Article |
- Wang, B. et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90, 4156−4160 (1993) | PubMed | ChemPort |
- Boyer, J.D. et al. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J. Med. Primatol. 25, 242−250 (1996). | PubMed | ISI | ChemPort |
- Lu, S., Santoro, J.C., Fuller, D.H., Haynes, J.R. & Robinson, H.L. Use of DNAs expressing HIV-1 envand non-infectious HIV-1 particles to raise antibody responses in mice. Virology 209, 147−154 (1995). | Article | PubMed | ISI | ChemPort |
- Haynes, J.R., Fuller, D.H., Eisenbraun, M.D., Ford, M.J., Pertmer, T.M. Accell
 particle-mediated DNA immunization elicits humoral, cytotoxic and protective responses. AIDS Res. Hum. Retrovlruses 10 (Suppl. 2), S43−S45 (1994).
- Okuda, K. et al. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res. Hum. Retroviruses 11, 933−943 (1995). | PubMed | ISI | ChemPort |
- Lu, S. et al. Simian Immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70, 3978−3991 (1996). | PubMed | ISI | ChemPort |
- Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Virol. 11, 6642−6647 (1993).
- Vandamme, A.-M. Polymerase chain reaction (PCR) as a diagnostic tool in HIV infection. Verh. K. Acad. Geneeskd. Belg. 3, 231−265 (1994).
- Vandamme, A.-M. et al. Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR. J. Virol. Methods 52 121−132 (1995). | Article | PubMed | ISI | ChemPort |
- Shibata, R. et al. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1. J. Virol. 70, 4361−4369 (1996). | PubMed | ISI | ChemPort |
- Lane, H.C., Depper, J.M., Greene, W.C., Whjalen, C., Waldmann, T.A. & Fauci, A.D. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: Evidence for a selective defect in soluble antigen recognition. N. Engl. J. Med. 313, 79−84 (1985). | PubMed | ISI | ChemPort |
- Gruters, R.A. et al. Selective loss of T cell functions in different stages of HIV infection, fur. J. Immunol. 20, 1038−1044 (1990).
- Vingerhoets, J.H. et al. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down-regulation on CD8+ T cells from HIV-infected subjects. Clin. Exp. Immun. 100, 425−433 (1995). | PubMed | ISI | ChemPort |
- Levine, B.L. et al. Antiviral effect and ex vivo CD4 T cell proliferation in HIV-positive patients as a results of CD28 costimulation. Science 272, 1939−1943 (1996). | PubMed | ISI | ChemPort |
- Brinchmann, J.E. et al. Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: Functional and clinical correlations. J. Infect. Dis. 169, 730−738 (1993). | ISI |
- Ho, D.D. et al. Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 infection. Nature 373, 123−126 (1995). | Article | PubMed | ISI | ChemPort |
- Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117−122 (1995). | Article | PubMed | ISI | ChemPort |
- Montifiori, D.C., Robinson, W.E., Schiffmann, S.S. & Michell, W.M. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Invest. 6, 231−235 (1988).
|
